A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
Latest Information Update: 20 Sep 2023
At a glance
- Drugs Gusacitinib (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Acronyms RADIANT
- Sponsors Asana BioSciences
Most Recent Events
- 27 May 2020 Status changed from recruiting to discontinued.
- 01 Oct 2018 Status changed from not yet recruiting to recruiting.
- 07 Sep 2018 New trial record